Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy-D-glucose and radiation: Implications for tumor therapy

Immunobiology

Volumn 221, Issue 2, 2016, Pages 269-281

  Farooque, Abdullah ^a   Afrin, Farhat ^b   Adhikari, Jawahar Singh ^a   Dwarakanath, Bilikere Srinivasa Rao ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

2 Deoxy D glucose (2 DG); Glycolysis; M1; Macrophages; Pro inflammatory; Radio sensitization

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; DEOXYGLUCOSE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR; CD86 PROTEIN, MOUSE; HLA ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DRUG CYTOTOXICITY; EHRLICH ASCITES TUMOR; EX VIVO STUDY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PHENOTYPE; POLARIZATION; RADIOSENSITIZATION; RAW 264.7 CELL LINE; SPLEEN; ANIMAL; CARCINOMA, EHRLICH TUMOR; CELL DIFFERENTIATION; CELL LINE; DRUG EFFECTS; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; PRIMARY CELL CULTURE; RADIATION RESPONSE; SIGNAL TRANSDUCTION; THERAPEUTIC USE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CARCINOMA, EHRLICH TUMOR; CELL DIFFERENTIATION; CELL LINE; DEOXYGLUCOSE; GAMMA RAYS; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2; MACROPHAGES, PERITONEAL; MALE; MICE; PHAGOCYTOSIS; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84948798898     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.10.009     Document Type: Article

References (48)

1. Barker, R.N., Erwig, L.P., Hill, K.S., Devine, A., Pearce, W.P., Rees, A.J., Antigen presentation by macrophage is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin. Exp. Immunol. 127 (2002), 220–225.
2. Bracci, L., Schiavoni, G., Sistigu, A., Belardelli, F., Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21 (2014), 15–25.
3. Brouckaert, G., Kalai, M., Krysko, D.V., Saelens, X., Vercammen, D., Ndlovu, M., Haegeman, G., D'Herde, K., Vandenabeele, P., Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol. Biol. Cell 15 (2004), 1089–1100.
4. Bryniarski, K., Szczepanik, M., Ptak, M., Zemelka, M., Ptak, W., Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol. Rep. 61 (2009), 550–557.
5. Chanmee, T., Ontong, P., Konno, K., Itano, N., Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6:3 (2014), 1670–1690.
6. Crespo, J., Sun, H., Welling, T.H., Tian, Z., Zou, W., T cell energy, exhaustion, senescence, and stemness in the tumor micro environment. Curr. Opin. Immunol. 25 (2013), 214–221.
7. DePalma, M., Lewis, C.E., Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23 (2013), 277–286.
8. Dwarakanath, B.S., Jain, V., Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol. 5:5 (2009), 581–585.
9. Dwarakanath, B.S., Jain, V.K., Modification of the radiation induced damage by 2-deoxy-d-glucose in organ cultures of human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 13 (1987), 741–746.
10. Dwarakanath, B.S., Jain, V.K., Energy linked modifications of the radiation response in a human cerebral glioma cell line. Int. J. Radiat. Oncol. Biol. Phys. 17 (1989), 1033–1040.
11. Dwarakanath, B.S., Singh, D., Banerji, A.K., Sarin, R., Venkataramana, N.K., Jalali, R., Vishwanath, P.N., Mohanti, B.K., Tripathi, R.P., Kalia, V.K., Jain, V., Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J. Cancer Res. Ther. 5:1 (2009), S21–S26.
12. Dwarakanath, B.S., Singh, S., Jain, V., Optimization of tumour radiotherapy: part V-radiosensitization by 2-deoxy-D-glucose and DNA ligand Hoechst-33342 in a murine tumour. Ind. J. Exp. Biol. 37 (1999), 865–870.
13. Dwarkanath, B.S., Zolzer, F., Chandna, S., Bauch, T., Adhikari, J.S., Muller, W.U., Streffer, C., Jain, V., Heterogeneity in of 2-deoxy-D-glucose induced modification of radiation response in human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001), 1051–1061.
14. Farooque, A., Afrin, F., Adhikari, J.S., Dwarakanath, B.S., Protection of normal cells and tissues during radio and chemosensitization of tumors by 2-deoxy-D-glucose. J. Cancer Res.Ther. 5 (2009), S32–S35.
15. Farooque, A., Mathur, R., Verma, A., Kaul, V., Bhatt, A.N., Adhikari, J.S., Afrin, F., Singh, S., Dwarakanath, B.S., Low-dose radiation therapy of cancer: role of immune enhancement. Expert Rev. Anticancer Ther. 11 (2011), 791–802.
16. Farooque, A., Singh, N., Adhikari, J.S., Afrin, F., Dwarakanath, B.S.R., Enhanced antitumor immunity contributes to the radio-sensitization of ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in mice. PLoS One, 9(9), 2014, e108131, 10.1371/journal.pone.0108131.
17. Farooque, A., Singh, S., Adhikari, J.S., Dwarakanath, B.S., Role of T regulatory cells (CD4+CD25+FoxP3+) and Th1, Th2 and Th3 cytokines in the radiosensization of Ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-d-glucose (2-DG). XXIV International Congress on Cytometry in the Age of Systems Biology, May 17–21, Budapest, Hungary, 2008, 156.
18. Farooque, A., Singh, S., Verma, A., Afrin, F., Adhikari, J., Dwarakanath, B., Activation of macrophages by the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) Implications for tumor therapy. Cancer Res., 69(May (1)), 2009, 3176.
19. Fortier, A.H., Falk, L.A., Isolation of Murine Macrophages. 1994, John Wiley & Sons, Inc., New York, 216.
20. Galván-Peña, S., O'Neill, L.A., Metabolic reprograming in macrophage polarization. Front. Immunol., 5(420), 2014.
21. Gupta, S., Farooque, A., Adhikari, J.S., Singh, S., Dwarakanath, B.S., Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. J. Cancer Res. Ther. 5 (2009), S16–S20.
22. Gupta, S., Mathur, R., Dwarakanath, B.S., The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in Ehrlich ascites tumor-bearing mice. Cancer Biol. Ther. 4 (2005), 87–94.
23. Hao, N.B., Lu, M.H., Fan, Y.H., Cao, Y.L., Zhang, Z.R., Yang, S.M., Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol., 2012, 2012, 10.1155/2012/948098.
24. Jain, V., Modifications of radiation responses by 2-deoxy-D-glucose in normal and cancer cells. Ind. J. Nucl. Med. 11 (1996), 8–17.
25. Jha, B., Pohlit, W., Effect of 2-deoxy-D-glucose on DNA double strand break repair, cell survival and energy metabolism in euoxic Ehrlich ascites tumour cells. Int. J. Radiat. Biol. 62 (1992), 409–415.
26. Kern, K.A., Norton, J.A., Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose. Surgery 102 (1987), 380–385.
27. Lamagna, C., Aurrand-Lions, M., Imhof, B.A., Dual role of macrophages in tumor growth and angiogenesis. J. Leukocyte. Biol. 80 (2006), 705–713.
28. Lee, Y.N., Lee, H.Y., Kang, H.K., Kwak, J.Y., Bae, Y.S., Phosphatidic acid positively regulates LPS-induced differentiation of RAW264.7 murine macrophage cell line into dendritic-like cells. Biochem. Biophys. Res. Commun. 318 (2004), 839–845.
29. Mantovani, A., In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages. Cancer Res. 37 (1977), 815–820.
30. Mantovani, A., Polentarutti, N., Luini, W., Peri, G., Spreafico, F., Role of host defense merchanisms in the antitumor activity of Adriamycin and daunomycin in mice. J. Natl. Cancer Inst. 63 (1979), 61–66.
31. Martinez, F.O., Gordon, S., 2014. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13.10.12703/P 6–13.
32. Mosmann, T., Rapid colorimetrie assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983), 55–63.
33. Murray, P.J., Wynn, T.A., Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11 (2011), 723–737.
34. Pelicano, H., Martin, D.S., Xu, R.H., Huang, P., Glycolysis inhibition for anticancer treatment. Oncogene 25 (2006), 4633–4646.
35. Pollard, J.W., Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004), 71–78.
36. Porcheray, F., Viaud, S., Rimaniol, A.C., Leone, C., Samah, B., Dereuddre-Bosquet, N., Dormont, D., Gras, G., Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 142 (2005), 481–489.
37. Ragsdale, R.L., Grasso, R.J., An improved spectrofluorometric assay for quantitating yeast phagocytosis in cultures of murine peritoneal macrophages. J. Immunol. Methods 123 (1989), 259–267.
38. Schmidt, A., Caron, E., Hall, A., Lipopolysaccharide-induced activation of beta 2-integrin function in macrophages requires Irak kinase activityp38 mitogen-activated protein kinase and the Rap1 gt pase. Mol. Cell Biol. 21 (2001), 438–448.
39. Sica, A., Mantovani, A., Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122 (2012), 787–795.
40. Solinas, G., Germano, G., Mantovani, A., Allavena, P., Tumor-associated macrophages (TAM) as major players of the cancer related inflammation. J. Leukoc. Biol. 86 (2009), 1065–1073.
41. Swamy, R.K., Manickam, J., Adhikari, J.S., Dwarakanath, B.S., Glycolytic inhibitor2-deoxy-D-glucose, does not enhance radiation-induced apoptosis in mouse thymocytes and splenocytes in vitro. Ind. J. Exp. Biol. 43 (2005), 686–692.
42. United Kingdom Coordinating Committee on Cancer Research (UKCCCR), Guidelines for the welfare of animals in experimental oncology. Br. J. Cancer 77 (1998), 1–10.
43. Venkataramana, N.K., Venkatesh, P.K., Dwarakanath, B.S., Vani, S., Protective effect on normal brain tissue during a combinational therapy of 2-deoxy-D-glucose and hypofractionated irradiation in malignant gliomas. Asian J. Neurosurg. 8 (2013), 9–14.
44. Weber, G., Cantero, A., Glucose-6-phosphatase activity in normalprecancerous, and neoplastic tissues. Cancer Res. 15 (1963), 105–108.
45. Weber, G.F., Zawaideh, S., Hikita, S., Kumar, V.A., Cantor, H., et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukoc. Biol. 72 (2002), 752–761.
46. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Andre, F., Tesniere, A., Kroemer, G., The anticancer immune response: indispensable for therapeutic success. J. Clin. Invest. 118 (2008), 1991–2001.
47. Zitvogel, L., Kepp, O., Kroemer, G., Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Rev. Clin. Oncol. 8 (2011), 151–160.
48. Zoelzer, F., Hillebrandt, S., Streffer, C., Radiation induced G1 block and p53 status in six human cell lines. Radioth. Oncol. 37 (1995), 20–28.